Forbes Article "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems"

Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Privo is excited to share the recent Forbes article titled, “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems” written by one of our manuscript authors, Alex Zhavoronkov, PhD that highlights our nanoengineered PRV Platform. Click the below to access the fill Forbes article.

Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems (forbes.com)

Link to Nature Communications publication on the PRV Platform is also provided below.

A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer | Nature Communications

Media Contact: communicationteam@privotechnologies.com

September 8, 2022

Author

'Peter Goldberg'

02DecDecember 2, 2018

MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

02DecDecember 2, 2022

Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

17NovNovember 17, 2025

PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial

Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a... read more

13SepSeptember 13, 2016

Privo Technologies Successfully Completes Phase 1/2 Study of PRV211 Intraoperative Chemotherapy for Head and Neck Cancer Patients Novel Surgical Innovation Demonstrates Excellent Safety Profile with Potential to Reduce Tumor Recurrence

BOSTON, January 23, 2026 – Privo Technologies, Inc. today announced the successful completion of its Phase 1/2 clinical evaluation of... read more

Forbes Article “Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation In Drug Delivery Systems”

Share this post

Author

Related Posts

Contact Us